Author

S. Assi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1

Frequent Co-Authors

P. N. Cockerill· 2 shared A. Adamo· 1 shared A. Akalin· 1 shared A. Krippner-Heidenreich· 1 shared A. Monzer· 1 shared A. Pfaus· 1 shared A. Ptasinska· 1 shared A. Reisser· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

P. N. Cockerill

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth

S. G. Kellaway, S. Potluri, P. Keane, H. Blair, P. S. Chin, A. Ptasinska, A. Worker, L. Ames, A. Adamo, D. J. Coleman, N. Khan, S. Assi, A. Krippner-Heidenreich, M. Raghavan, P. N. Cockerill, , C. Bonifer

This study identifies VEGF and IL-5 signalling pathways as aberrantly activated in t(8;21) leukemic stem cells, enabling their growth and relapse.

bioRxiv · Mar 10, 2023Cancer Biology

A new type of transcriptional reprogramming by an IRF4 mutation in lymphoma

N. Schleussner, P. Cauchy, V. Franke, M. Giefing, O. Fornes, N. Vankadari, S. Assi, M. Costanza, M. A. Weniger, A. Akalin, I. Anagnostopoulos, T. Bukur, M. G. Casarotto, F. Damm, O. Daumke, , R. Grosschedl

This study identifies a mutation in IRF4 that alters DNA-binding specificity and gene regulation in lymphoma, leading to disease-specific gene up-regulation.

bioRxiv · Dec 29, 2022 · PreprintCancer Biology

Specific Inhibition of GSK-3β by Tideglusib: Potential Therapeutic Target for Neuroblastoma Cancer Stem Cells

H. F. Bahmad, R. M. Chalhoub, H. Harati, J. Bou-Gharios, F. Ballout, A. Monzer, H. Msheik, S. Assi, T. Araji, M. K. Elajami, P. Ghanem, F. Chamaa, H. Kadara, T. Abou-Antoun, G. Daoud, , W. Abou-Kheir

This study evaluates Tideglusib's effectiveness in inhibiting neuroblastoma cell proliferation, viability, migration, and CSC self-renewal both in vitro and in vivo.

bioRxiv · Feb 18, 2020 · PreprintCancer Biology